谷氨酰胺多疾病防护机制：2025孟德尔随机化研究最新解读

Recent studies have shown that, in addition to LOMG, glutamine exerts protective effects on various immune-related diseases. A Mendelian randomization study on inflammatory bowel disease (IBD) found a significant negative correlation between glutamine and IBD risk (OR=0.551, P=0.014), with a particularly notable protective effect against Crohn's disease (OR=0.375, P=1.11×10⁻⁶) (DOI: 10.7150/jca.96085). Glutamine also demonstrated a protective effect against alopecia areata (OR=0.59, P<0.05) (DOI: 10.1097/MD.0000000000046312), and similar results were reported in a study on allergic rhinitis (OR=0.874, P=0.036) (DOI: 10.1097/MD.0000000000045400). These findings corroborate the protective role of glutamine in multiple autoimmune diseases, enhancing the reliability of our study results. Additionally, glutamine has shown positive effects on skeletal muscle function. A Mendelian randomization study on sarcopenia indicated a protective effect of glutamine on muscle metabolism (DOI: 10.1016/j.clnu.2025.02.020), suggesting its potential value in maintaining skeletal muscle function. These findings align with our study results, collectively supporting the notion that glutamine may exert protective effects against late-onset myasthenia gravis through multiple mechanisms, including immune modulation and support of skeletal muscle metabolism.